NKTR CEO Robin sold 20,000 shares for $1.2M via scheduled 10b5-1 plan; stock -44.1% from 52-week high, company unprofitable with -43.9% revenue decline.
Howard W Robin, President & CEO of Nektar Therapeutics, executed 4 separate sales totaling 20,000 shares for $1,215,055.78 at an average price of $60.75 on June 16–17, 2026. This transaction was conducted under a pre-arranged 10b5-1 trading plan adopted on 2026-03-13, making it a scheduled rather than discretionary sale. The sale reduced his holdings from 75,045 shares to 55,045 shares, a reduction of 20,000 shares. The context surrounding this sale is material: the company posted quarterly revenue of $10,861,000.00 with net income of -$44,904,000.00, and full-year net income was negative; annual revenue growth was -43.9%. The stock is currently trading at $60.98, -44.1% below its 52-week high of $109.00. Investors should note that this is a scheduled plan execution occurring during a period of operational decline and significant stock depreciation, though the scheduled nature of the plan removes any timing signal from the transaction itself.